Document is current

Any future updates will be listed below

386 Non-relapse mortality and immune-related adverse events with lifileucel: a post-marketing surveillance analysis

Crossref DOI link: https://doi.org/10.1136/jitc-2025-SITC2025.0386

Published Online: 2025-11-04

Published Print: 2025-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark